Literature DB >> 125204

Cassaine: mechanism of inhibition of Na+ +K+ -ATPase and relationship of this inhibition to cardiotonic actions.

T Tobin, T Akera, S L Brody, D Ku, T M Brody.   

Abstract

The erythrophleum alkaloid cassaine shares many of the pharmacological actions of the cardiac glycosides but lacks the structural characteristics typical of cardiac glycosides. To further investigate the relationship between Na+ +K+ -ATPase inhibition and the cardiotonic actions of these drugs we investigated the interaction of cassaine with the Na+ +K+ -ATPase. Cassaine inhibited rat brain Na+ +K+ -ATPase with about one quarter of the apparent affinity of ouabain for this enzyme. This inhibition was non-competitive with respect to K+. Cassaine also inhibited this enzyme in the presence of Mg2+ and this inhibition was enhanced by Pi and antagonized by Na+. In the presence of Na+, Mg2+ and (gamma-32P)-ATP cassaine acted to stabilize the phosphorylated intermediate of Na+ +K+ -ATPase. Cassaine also acted to displace specifically bound (3H)-ouabain from this enzyme. These observations suggested that cassaine inhibited the Na+ +K+ -ATPase by interacting at the cardiotonic steroid binding sites of Na+ +K+ -ATPase. Consistent with this hypothesis, dog, guinea pig and rat heart Na+ +K+ -ATPase showed differing sensitivities to cassaine paralleling their differing sensitivities to ouabain. The principal difference between the interaction of cassaine and ouabain with Na+ +K+ -ATPase appeared to be the more rapid dissociation of cassaine from the cardiotonic steroid binding site(s) of Na+ +K+ -ATPase. In keeping with this the rates of offset of cassaine-induced inotropy in Langendorff perfused dog and guinea pig hearts were several times faster than those of ouabain-induced inotropy.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 125204     DOI: 10.1016/0014-2999(75)90276-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Biochemical basis for the low sensitivity of the rat heart to digitalis.

Authors:  T Akera; S Yamamoto; J Chubb; R McNish; T M Brody
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-08       Impact factor: 3.000

2.  Reduction of the equilibrium binding of cardiac glycosides and related compounds to Na+,K+-ATPase as a possible mechanism for the potassium-induced reversal of their toxicity.

Authors:  T Akera; K Temma; S A Wiest; T M Brody
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-09       Impact factor: 3.000

3.  Membrane potential-dependent inhibition of the Na+,K+-ATPase by para-nitrobenzyltriethylammonium bromide.

Authors:  R Daniel Peluffo; Joshua R Berlin
Journal:  Mol Pharmacol       Date:  2012-03-28       Impact factor: 4.436

4.  Kinetics of the inhibition of the Na-K pump by tetrapropylammonium chloride.

Authors:  D L Kropp; J R Sachs
Journal:  J Physiol       Date:  1977-01       Impact factor: 5.182

5.  The lead structure in cardiac glycosides is 5 beta, 14 beta-androstane-3 beta 14-diol.

Authors:  W Schönfeld; J Weiland; C Lindig; M Masnyk; M M Kabat; A Kurek; J Wicha; K R Repke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-06       Impact factor: 3.000

6.  Cardiac Glycosides Activate the Tumor Suppressor and Viral Restriction Factor Promyelocytic Leukemia Protein (PML).

Authors:  Snezana Milutinovic; Susanne Heynen-Genel; Elizabeth Chao; Antimone Dewing; Ricardo Solano; Loribelle Milan; Nikki Barron; Min He; Paul W Diaz; Shu-ichi Matsuzawa; John C Reed; Christian A Hassig
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.